

1 **Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a**
2 **population-based sample**

3 Silvia Stringhini^{1,2,3}, Ania Wisniak⁴, Giovanni Piumatti^{1,8}, Andrew S. Azman⁵, Stephen A.
4 Lauer⁵, H el ene Baysson², David De Ridder², Dusan Petrovic^{1,3}, Stephanie Schrempft¹, Kailing
5 Marcus¹, Sabine Yerly^{6,9}, Isabelle Arm Vernez⁹, Olivia Keiser⁴, Samia Hurst⁷, Klara M.
6 Posfay-Barbe^{2,10}, Didier Trono¹¹, Didier Pittet¹², Laurent G etaz^{1,2}, Fran ois Chappuis^{1,2},
7 Isabella Eckerle^{2,6,9}, Nicolas Vuilleumier^{2,6}, Benjamin Meyer^{2,13}, Antoine Flahault^{1,2,4}, Laurent
8 Kaiser^{2,6,9}, Idris Guessous^{1,2}

- 9
- 10 1. Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland
 - 11 2. Faculty of Medicine, University of Geneva, Geneva, Switzerland
 - 12 3. University Centre for General Medicine and Public Health, University of Lausanne,
13 Lausanne, Switzerland
 - 14 4. Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva,
15 Switzerland
 - 16 5. Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology,
17 Baltimore, USA
 - 18 6. Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland
 - 19 7. Institut Ethique, Histoire, Humanit es, University of Geneva, Geneva, Switzerland
 - 20 8. Faculty of BioMedicine, Universit  della Svizzera italiana, Lugano, Switzerland
 - 21 9. Geneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva
22 University Hospitals, Geneva, Switzerland
 - 23 10. Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland
24 a. School of Life Sciences, Ecole Polytechnique F d rale de Lausanne (EPFL),
25 Lausanne, Switzerland
 - 26 11. Infection Prevention and Control program and World Health Organization (WHO)
27 Collaborating Centre on Patient Safety, Geneva University Hospitals, Geneva,
28 Switzerland
 - 29 12. Centre for Vaccinology, Department of Pathology and Immunology, University of
30 Geneva, Geneva, Switzerland

31
32 **Keywords:** Seroprevalence, anti-SARS-CoV2 IgG, representative survey, Europe

33 **Correspondence:**

34 Dr. Silvia Stringhini, e-mail: silvia.stringhini@hcuge.ch
35 Address: Rue Gabrielle-Perret-Gentil 4, 1205 Gen ve
36 Phone: +41 22 372 33 11

37
38 **Words count:**

39 Full text: 2289

40 Abstract: 321

41 **Abstract**

42 **Background:** Assessing the burden of COVID-19 based on medically-attended case counts is
43 suboptimal given its reliance on testing strategy, changing case definitions and the wide spectrum of
44 disease presentation. Population-based serosurveys provide one avenue for estimating infection rates
45 and monitoring the progression of the epidemic, overcoming many of these limitations.

46
47 **Methods:** Taking advantage of a pool of adult participants from population-representative surveys
48 conducted in Geneva, Switzerland, we implemented a study consisting of 8 weekly serosurveys among
49 these participants and their household members older than 5 years. We tested each participant for anti-
50 SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay
51 (Euroimmun AG, Lübeck, Germany). We estimated seroprevalence using a Bayesian regression model
52 taking into account test performance and adjusting for the age and sex of Geneva's population.

53
54 **Results:** In the first three weeks, we enrolled 1335 participants coming from 633 households, with
55 16% <20 years of age and 53.6% female, a distribution similar to that of Geneva. In the first week, we
56 estimated a seroprevalence of 3.1% (95% CI 0.2-5.99, n=343). This increased to 6.1% (95% CI 2.6-
57 9.33, n=416) in the second, and to 9.7% (95% CI 6.1-13.11, n=576) in the third week. We found that
58 5-19 year-olds (6.0%, 95% CI 2.3-10.2%) had similar seroprevalence to 20-49 year olds (8.5%,
59 95%CI 4.99-11.7), while significantly lower seroprevalence was observed among those 50 and older
60 (3.7%, 95% CI 0.99-6.0, p=0.0008).

61
62 **Interpretation:** Assuming that the presence of IgG antibodies is at least in the short-term associated
63 with immunity, these results highlight that the epidemic is far from burning out simply due to herd
64 immunity. Further, no differences in seroprevalence between children and middle age adults are
65 observed. These results must be considered as Switzerland and the world look towards easing
66 restrictions aimed at curbing transmission.

67

68 **Introduction**

69 Although statistics on confirmed cases and deaths help in monitoring the dynamics of disease
70 propagation, estimates remain largely unreliable when trying to understand the proportion of the
71 population infected with SARS-CoV-2 for public health purposes ¹. For example, until recently most
72 European countries, including Switzerland, did not have sufficient nasopharyngeal swabs available for
73 RT-PCR screening of anyone suspected or at risk of infection with SARS-CoV-2. Generally,
74 asymptomatic individuals, including those in at-risk categories, are not screened. As a result, the
75 number of confirmed cases of SARS-CoV-2 infections is largely underestimated ². In this context,
76 seroprevalence surveys are of utmost importance for understanding the proportion of the population
77 that has already developed antibodies against the virus and is potentially protected towards a new
78 infection ³. As recommended by the World Health Organization (WHO), monitoring changes of
79 seroprevalence over time is also crucial at the beginning of an epidemic to anticipate and plan an
80 adequate public health response ⁴.

81

82 The canton of Geneva, Switzerland, reported its first confirmed COVID-19 case on February 26, with
83 5071 cases (10.15 per 1000 inhabitants) and 243 deaths as of April 30 ^{5,6}. As in most countries,
84 changing testing strategies over the course of the epidemics made it impossible to estimate the extent
85 of the population that had been infected, while this information is crucial to plan evidence-based
86 strategies to lift confinement measures. To assess the seroprevalence of anti-SARS-CoV-2 antibodies
87 in this area, we initiated a survey in a representative sample of the population ⁷. To do so, we
88 contacted subjects who already participated in the Bus Santé study (an annual health examination
89 survey of a representative sample of the population of the canton) ⁸ and invited them along with their
90 household members to participate to the SEROCov-POP seroprevalence survey ⁷. Here we present
91 results based on 1335 participants who took part to the study during the first 3 of 12 study weeks as
92 they are likely to inform public health policy makers in Europe and beyond.

93

94 **Methods**

95 *Study Design*

96 Each week, ~1300 randomly selected previous participants of the Bus Santé study with an email
97 address on file (n~10'072, **Figure S1**) were invited to participate in the SEROCov-POP study by
98 email, which provided a link to an online appointment booking system for a visit at one of two sites
99 within the proceeding seven days. Eligible participants with a non-valid email address were contacted
100 by phone to update their contact information. Since the third study week, each potential participant
101 that hadn't replied to the initial email invitation within 72h was reminded of the invitation by phone, in
102 order to increase participation rate. Potential participants then received a confirmation by email, which
103 included a link to a questionnaire and a consent form to complete at home and bring on the day of the
104 study visit. During the visit, study staff discussed the study once again with participants to ensure

105 informed consent. Participants were invited to bring all members of their household, aged 5 years and
106 older, to join the SEROCO-V-POP study. An electronic validation system allowed participants to
107 declare that they weren't in quarantine or isolation and didn't present with symptoms compatible with
108 COVID-19 at the moment of making the appointment, in which case they were encouraged to book at
109 a further date. Participants considered vulnerable according to the Swiss Federal Office of Public
110 Health criteria ⁹ (over 65 years old, diabetic, suffering from cardio-vascular or respiratory disease,
111 immunocompromised, suffering from active cancer or with a BMI > 35 kg/m²) were asked to contact
112 us directly by phone or email to book an appointment on time slots reserved explicitly for this
113 population, in order to reduce risk of exposure to the virus. Inclusion criteria included people aged 5
114 years and older, whose primary residence was in the canton of Geneva. Over the first 3 weeks, 31% of
115 invited eligible participants took part in the study, 16% refused to participate, and 53% have a pending
116 status (waiting for booking appointment, being recalled, etc). We collected 6 mL of peripheral venous
117 blood from each adult participant and 3 mL from each child less than 14 years old. The SEROCO-V-
118 POP study was approved by the Cantonal Research Ethics Commission of Geneva, Switzerland
119 (CER16-363).

120

121 *Laboratory Analyses*

122 We assessed anti-SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked
123 immunosorbent assay (Euroimmun AG, Lübeck, Germany # EI 2606-9601 G) targeting the S1-domain
124 of the spike protein of SARS-CoV-2; sera diluted 1:101 were processed on a EuroLabWorkstation
125 ELISA. An in-house validation study, using a set of sera from 176 pre-pandemic negative controls and
126 181 RT-PCR confirmed COVID-19 cases was conducted to estimate test performance and optimal
127 thresholds for definitive results ¹⁰. Based on this validation study, which set thresholds to maximize
128 specificity and inter-assay variability in test classification, we considered those with OD/CI >= 1.5 to
129 be positive. This threshold resulted in a sensitivity of 86.2% and a specificity of 100%. For these
130 analyses we treated all indeterminate results (>0.5 OD/CI <1.5) as negatives (Figure S1).

131

132 *Statistical Methods and Analyses*

133 To estimate seroprevalence, we used a simple Bayesian regression model taking into account test
134 performance, in addition to the age and sex of the population. In this framework, our goal is to
135 estimate the true underlying seroprevalence, p , within the population:

136

$$137 \quad x_i \sim \text{Bernoulli}(p_i \theta^+ + (1 - p_i) * (1 - \theta^+))$$

$$138 \quad \text{logit}(p_i) = X\beta + \varepsilon_i$$

$$139 \quad x^+ \sim \text{Binomial}(n^+, \theta^+)$$

$$140 \quad x^- \sim \text{Binomial}(n^-, 1 - \theta^+)$$

$$141 \quad \varepsilon_i \sim \text{Normal}(0, \sigma^2)$$

142

143 where x_i is the result of the IgG ELISA for the i th person ($i = 1, \dots, N$). The sensitivity, θ^+ , is
144 determined using n^+ RT-PCR positive controls from the lab validation study, of which x^+ tested
145 positive. The specificity, θ^- , is determined using n^- pre-pandemic negative controls, of
146 which x^- tested positive. The probability of observing a diagnostic positive is a function of the true
147 positive rate and the false negative rate with regards to the true underlying probability of
148 seropositivity p_i . This probability itself is a function of covariates X , which consists of sex, age
149 categories, and week of study, and their coefficients β as well as an error term, ϵ_i with variance σ^2 .
150 We used naive priors on all parameters to allow for an exploration of the parameter space. We
151 implemented this model in the Stan probabilistic programming language¹¹ and used the *rstan* package
152 to run the model, analyse outputs. We ran 20,000 iterations with 4 chains and assessed convergence
153 visually and using the R-hat statistic. While we did not account for household clustering specifically in
154 this model, we developed a separate hierarchical model with a random intercept for household,
155 including the modeling of test performance but with no covariates. We used this model to estimate the
156 overall seroprevalence across the three weeks and compared to those from the model described above
157 to understand the potential impact of not accounting for clustering within households.

158

159 To generate seroprevalence estimates adjusted to the age and sex distribution of the population, we
160 sampled from the posterior for all age-sex strata proportional to the demographics in canton of
161 Geneva. All estimates presented represent the mean of the posterior samples with the 2.5th and 97.5th
162 percentiles of this distribution as the 95% confidence intervals (95%CI).

163

164 **Results**

165 In the first three weeks of the study starting on April 6, we enrolled a total of 1335 individuals in the
166 SEROCOv-POP survey (Figure S2). Included participants came from 633 different households, with
167 53.6% being female, and 16% being under 20 years of age (**Table 1**), displaying a similar distribution
168 to that of the overall Geneva population¹². While 246 individuals participated alone to the study, 193
169 participants came with one other household member, 97 participants with two household members,
170 and 97 participants with three or more household members.

171

172 In the first week, we estimated an overall seroprevalence of 3.1% (95% CI 0.2-5.9). This figure
173 increased to 6.1% (95%CI 2.6-9.33, n=416) in the second week, and to 9.7% (95% CI 6.1-13.1,
174 n=576) in the third week, mirroring the increase in confirmed cases in the weeks before the survey
175 (**Figure 1**). While there were no meaningful differences in seroprevalence between men and women
176 (**Table 1**), we found that 5-19 year olds (6.0%, 95% CI 2.3-10.2%) had a similar seroprevalence to 20-
177 49 year olds (8.5%, 95% CI 4.9-11.7), whereas seroprevalence among those 50 and older (3.7%, 95%
178 CI 0.9-6.0, p<0.01) was significantly lower.

179

180 As a sensitivity analysis, we estimated seroprevalence among the subset of participants who were
181 originally enrolled in our previous representative surveys (**Table 2**). Within this subset, we observed
182 similar seroprevalence as in the overall study population, with higher estimates in younger individuals
183 (20-49 years vs. 50+ years), and with increasing seroprevalence estimates from the first to the third
184 week of the study.

185

186 **Discussion**

187 The preliminary results of this study provide an important benchmark to assess the state of the
188 epidemic. With an estimated 48'500 people having developed antibodies (9.7% of 500'000
189 inhabitants) while 4741 cases were confirmed on April 24th⁵, we observe that there are roughly 10
190 infections for every COVID-19 confirmed case in Geneva, reflecting the variability in disease severity,
191 testing practices and care-seeking behaviors. Further, we show that three weeks after the peak of
192 confirmed cases, only 1 in 10 people has developed antibodies against SARS-CoV-2, even in one of
193 the more heavily affected areas in Europe¹³. Thus, assuming that the presence of IgG antibodies
194 measured in this study is at least in the short-term associated with immunity, these results highlight
195 that the epidemic is far from burning out simply due to herd immunity. Given the time to development
196 of IgG antibodies (1-3 weeks), we expect to continue seeing significant increases in seroprevalence
197 over the coming weeks¹⁴.

198

199 We found no differences in seroprevalence between children/young-adults (5-19 years old) and middle
200 age adults, with those older than 50 years having a significantly lower seroprevalence than 20-49 year
201 olds. Although children present typical COVID-19 symptoms far less frequently than adults, these
202 results provide support to emerging research showing that they indeed get infected at similar rates¹⁵.
203 This should be considered in view of increased concerns about severe inflammatory syndromes in
204 children that could be COVID-19-related¹⁶, and of the worldwide debate around opportunity and
205 modality of school re-openings. While the sample size of older adults was small, the lower
206 seroprevalence estimates in this group suggest that targeted efforts to reduce social mixing of elderly
207 people with others may have succeeded. However, it remains possible that, because of an age-related
208 compromised ability to generate adaptive immune responses, the elderly develop a lower IgG response
209 after infection, something that needs further investigation¹⁷.

210

211 To our knowledge, this is the first study to perform a large-scale seroprevalence survey of anti-SARS-
212 CoV-2 IgG antibodies where participants were selected from a representative sample of the general
213 population. It is also unique in its repeated nature allowing the study of immunity dynamics in both
214 adult and children populations. Our population-based design as well as the fact that we informed
215 participants that individual results were not going to be disclosed until the end of the study, mitigate

216 selection bias. This study applies advanced statistical methods accounting for demographic structure
217 and imperfect diagnostic test to estimate seroprevalence in the overall population while capturing
218 uncertainty in the estimates.

219

220 Our study also has some important limitations to acknowledge. First, the primary analyses include
221 randomly selected participants as well as members of their households, making this sample not
222 entirely randomly selected. We attempt to adjust for some aspects of this through poststratification
223 within our statistical model. Further, in sensitivity analyses we estimated the seroprevalence for just
224 the original and found that it is similar to that of the full sample. Second, we were able to account for
225 clustering within households only for overall prevalence pooling the three weeks, as there was not
226 enough data to account for age, sex, and household clustering all together within this framework. The
227 use of a random effects model to account for household clustering did not change pooled results.
228 Finally, the recruitment of participants by email might exclude non tech-proficient individuals or
229 people without access to technology; another survey specifically targeting vulnerable populations
230 (socially and clinically) is ongoing.

231

232 Over the next weeks, we will continue monitoring weekly seroprevalence in the general population
233 and will be able to provide more refined analysis on symptomatology and other socio-demographic
234 data in relation to immunological status. Yet, a preliminary presentation of these results is deemed to
235 be necessary to timely inform global policy makers on how to adapt planning of the next phases.
236 Public sharing of our protocol can also help the global academic community to implement serosurveys
237 in their areas. For at least one year, we will follow up participants via an online digital platform and
238 repeated serological/RT-PCR testing in order to assess COVID19 incidence in the population. These
239 longitudinal results will also inform us on the dynamics of immunity which remain debated at this
240 stage.

241

242 Our results highlight that as hospitalizations have reduced in Geneva and other similar locations
243 throughout the world, the immunologic landscape has not changed greatly since the onset of the
244 pandemic, with the vast majority of people having no evidence of past infection. As the world
245 develops plans to find a new balance between minimizing the direct impacts of COVID-19 on those
246 infected and the indirect effects on all of society, serologic studies such as this are critical for
247 providing new insights about transmission and the otherwise hidden immunologic state of the
248 population.

249

250

251

252

253

254 **Acknowledgments**

255 This study would not have been possible without the instrumental and passionate contribution of the
256 staff of the Unit of Population Epidemiology of the HUG Primary Care Division (Natacha Noel,
257 Caroline Pugin, Jane Portier, Barinjaka Rakotomiramanana, Leila Botudi, Natalie Francioli, Paola
258 d'Ippolito, Chantal Martinez, Francesco Pennacchio, Benjamin Emery, Zoé Waldman, Magdalena
259 Schellongova, Prune Collombet), of the team of the Division of Laboratory Medicine (Géraldine
260 Poulain and Pierre Lescuyer), of the HUG staff affected to our unit during the COVID emergency
261 (Lilas Salzman-Bellard, Mélanie Seixas Miranda, Yasmina Malim, Acem Gonul, Odile Desvachez)
262 and finally without the invaluable work of the medical students who have invested their time and
263 energy in this project (Jonathan Barbolini, Eugénie de Weck, Natacha Michel, Emmanuelle Mohbat,
264 Irine Sakvarelidze, Céline Eelbode, Sultan Bahta, Céline Dubas, Lina Hassar, Melis Kir, Hugo-Ken
265 Oulevey, Kouros Massiha, Manon Will, Natacha Vincent, Fanny Lombard, Alioucha Davidovic,
266 Benoit Favre, Amélie Mach, Eva Marchetti, Sophie Cattani, Joséphine Duc, Julie Guérin, Soraya
267 Maret, Francesca Hovagemyan, Antoine Daeniker, Rebecca Buetzberger). We also thank Professor
268 Nicola Low for her insight and help in designing the study, as well as all the participants of the Bus
269 Santé Study and their household members.

270

271 **Funding**

272 This study was funded by the Swiss Federal Office of Public Health, The Swiss School of Public
273 Health, the Fondation de Bienfaisance du Groupe Pictet, the Fondation Ancrege, the Fondation Privée
274 des HUG, the Center for Emerging Viral Diseases. The funders had no role in study design, data
275 collection and analysis, decision to publish, or preparation of the manuscript.

276

277 **Author's contribution**


278 SS, AW, AF, LK and IG conceived the study. SS and IG drafted the first version of the manuscript.
279 AA, AW, DP contributed to drafting sections of the manuscript. AA, SL and GP performed data
280 analyses. SY, IAV, IE, NV, BM, LK performed lab analysis. GP, HB, AA, SL, DDR, DP, StS, KM,
281 OK, SH, KPB, DT, DP, LG, FC participated in the study design and helped to draft the manuscript.
282 All authors contributed to the interpretation of data, and read and approved the final manuscript.

283

284 **Conflicts of interest to disclose**

285 No author had conflicts of interest to disclose.

286 **Figure 1.** Seroprevalence estimates and 95% confidence interval (CI)s for each week of the survey
287 (A), daily confirmed cases reported in Geneva (B) and cumulative case counts per day and cumulative
288 incidence rate of confirmed COVID-19 (C).



289
290
291


Red bars represent the periods where individuals were tested in each study week. IgG antibodies may take up to 3 weeks to develop.

292 **Table 1:** Overview of sample size and seroprevalence estimates by week, sex and age. Note that p-
293 values are Bayesian p-values following Gelman et al. ¹⁸.

	n	positive	seroprevalance	p-value
<i>Age</i>				
5-19	214	13 (6.1%)	6.0, 95% CI (2.3-10.2)	0.12
20-49	538	45 (8.4%)	8.5, 95% CI (4.9-11.7)	-
50+	583	25 (4.3%)	3.7, 95% CI (0.9-6.0)	<0.001
<i>Sex</i>				
Female	715	40 (5.6%)	5.6, 95% CI (3.1-8.1)	-
Male	620	43 (6.9%)	6.9, 95% CI (3.3-9.9)	0.24
<i>Week</i>				
Week 1	343	11 (3.2%)	3.1, 95% CI (0.2-5.9)	0.03
Week 2	416	22 (5.3%)	6.1, 95% CI (2.6-9.33)	-
Week 3	576	50 (8.7%)	9.7, 95% CI (6.1-13.1)	0.03

294

295 **Figure S1.** Flow chart of inclusion in the study.



296

297

298


299 **Table S1:** Overview of sample size and seroprevalence estimates by week, sex and age (Bus Santé
300 randomly selected participants only – other household members were excluded).

301

	n	positive	seroprevalance	p-value
<i>Age</i>				
20-49	253	2222 (8.7%)	9.5, 95% CI (5.3-14.0)	-
50+	375	15 (4.0%)	3.7, 95% CI (1.0-6.4)	0.00
<i>Sex</i>				
Female	340	1616 (4.7%)	5.7, 95% CI (2.8-9.1)	-
Male	288	21 (7.3%)	8.0, 95% CI (3.7-12.5)	0.19
<i>Week</i>				
Week 1	156	4 (2.6%)	3.0, 95% CI (0.1-7.2)	0.02
Week 2	190	12 (6.3%)	8.3, 95% CI (4.1-13.4)	-
Week 3	282	21 (7.4%)	9.0, 95% CI (4.5-13.7)	0.39

302

303 **Figure S2.** Density of ELISA ratios for all participants colored by result interpretation. All
304 indeterminates were considered negative for these analyses.



305

306

307

308 **References**

309

310 1 Roda WC, Varughese MB, Han D, Li MY. Why is it difficult to accurately predict the COVID-19
311 epidemic? *Infectious Disease Modelling* 2020.

312 2 Verity R, Okell LC, Dorigatti I, *et al.* Estimates of the severity of coronavirus disease 2019: a
313 model-based analysis. *The Lancet Infectious Diseases* 2020.

314 3 Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed.
315 *New England Journal of Medicine* 2020; **382**: 1194–1196.

316 4 World Health Organization. Population-based age-stratified seroepidemiological investigation
317 protocol for COVID-19 virus infection. *Version* 2020; **1**: 17.

318 5 Office Fédéral de la Santé Publique. Rapport sur la situation épidémiologique en Suisse et dans la
319 Principauté de Liechtenstein. 2020; published online April 30.
320 [https://www.bag.admin.ch/bag/fr/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-](https://www.bag.admin.ch/bag/fr/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html#1164290551)
321 [ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html#1164290551](https://www.bag.admin.ch/bag/fr/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html#1164290551) (accessed
322 April 30, 2020).

323 6 République et canton de Genève. COVID-19: Situation épidémiologique à Genève. GE.CH –
324 République et canton de Genève. 2020; published online April 29.
325 <https://www.ge.ch/document/covid-19-situation-epidemiologique-geneve> (accessed April 30,
326 2020).

327 7 Primary Care Division-Geneva University Hospitals H. Repeated seroprevalence survey of anti-
328 SARS-CoV-2 IgG antibodies in the population of the canton of Geneva. Geneva, Switzerland, 2020
329 [https://static1.squarespace.com/static/5e7dd8f02d3bc353fbb05121/t/5e887016c7fa18312c3e00fa/1](https://static1.squarespace.com/static/5e7dd8f02d3bc353fbb05121/t/5e887016c7fa18312c3e00fa/1585999900784/Protocole_SEROCOV-POP30.03.pdf)
330 [585999900784/Protocole_SEROCOV-POP30.03.pdf](https://static1.squarespace.com/static/5e7dd8f02d3bc353fbb05121/t/5e887016c7fa18312c3e00fa/1585999900784/Protocole_SEROCOV-POP30.03.pdf).

331 8 Guessous I, Gaspoz J-M, Theler J-M, Wolff H. High prevalence of forgoing healthcare for
332 economic reasons in Switzerland: a population-based study in a region with universal health
333 insurance coverage. *Preventive medicine* 2012; **55**: 521–7.

334 9 Conseil fédéral. RS 818.101.24 Ordonnance 2 du 13 mars 2020 sur les mesures destinées à lutter
335 contre le coronavirus (COVID-19) (Ordonnance 2 COVID-19).
336 <https://www.admin.ch/opc/fr/classified-compilation/20200744/index.html> (accessed April 30,
337 2020).

338 10 Meyer B, Torriani G, Yerly S, *et al.* Validation of a commercially available SARS-CoV-2
339 serological Immunoassay. Unpublished manuscript. .

340 11 Carpenter B, Gelman A, Hoffman MD, *et al.* Stan: A probabilistic programming language. *Journal*
341 *of statistical software* 2017; **76**.

342 12 République et canton de Genève. Statistiques cantonales - République et canton de Genève-T
343 01.01.8.01: Population résidante selon l'origine, le sexe, le groupe d'âges et l'état matrimonial,
344 depuis 2013. https://www.ge.ch/statistique/domaines/01/01_01/tableaux.asp#5 (accessed April 30,
345 2020).

346 13 WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 99. Geneva, Switzerland, 2020
347 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-99-covid-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-99-covid-19.pdf?sfvrsn=119fc381_2)
348 [19.pdf?sfvrsn=119fc381_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-99-covid-19.pdf?sfvrsn=119fc381_2).

- 349 14 Huang AT, Garcia-Carreras B, Hitchings MD, *et al.* A systematic review of antibody mediated
350 immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody
351 responses with severity of disease. *medRxiv* 2020.
- 352 15 Bi Q, Wu Y, Mei S, *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of
353 their close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet Infectious*
354 *Diseases* 2020.
- 355 16 Jones VG, Mills M, Suarez D, *et al.* COVID-19 and Kawasaki disease: novel virus and novel case.
356 *Hospital Pediatrics* 2020; : hpeds-2020.
- 357 17 Pawelec G, Weng N. Can an effective SARS-CoV-2 vaccine be developed for the older
358 population? 2020.
- 359 18 Gelman A, Meng X-L, Stern H. Posterior predictive assessment of model fitness via realized
360 discrepancies. *Statistica sinica* 1996; : 733–60.
- 361